Today's top stories from ASCO 2024 include AstraZeneca taking a solid tumor CAR-T for liver cancer to a Phase 2 clinical trial.

ASCO: With hopes high, Regeneron misses mark with just one complete response in solid tumor trial so far. By Gabrielle Masson May 23, 2024 5:00pm. Regeneron Pharmaceuticals ASCO 2024 Clinical ...

ASCO showcased the payoff for new cancer medicines: longer lives. By Matthew Herper, Angus Chen, Adam Feuerstein, and Katherine MacPhail June 7, 2023. Reprints.

Erica Campbell chose a mastectomy. That choice gave her power — and helped her make peace with her biggest regret.

ASCO 2023: Opening Session Newsletter Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Context Therapeutics Inc. (NASDAQ:CNTX) is one of the best penny stocks under $1 to buy now. Earlier in June, Context ...

Mersana Therapeutics Inc. (NASDAQ:MRSN) is one of the best penny stocks under $1 to buy now. Earlier in June, Mersana ...

An expert discusses how long-term follow-up data from the COMMANDS trial demonstrated sustained superiority of luspatercept ...

A different study presented at the 2025 ASCO Annual Meeting showed that one specific diet may benefit people with colon ...

Cancer research saves lives and leads to improved outcomes for patients. But federal cancer research funding may be in jeopardy for 2026.

ASCO, for its part, tried (futilely) to help attendees navigate the murky waters. Upon registration, attendees could choose to don a red pin (keep a 6-foot distance), ...